Observational studies and smaller clinical trials have examined men with obesity and type 2 diabetes treated with GLP-1 receptor agonists, including semaglutide
It is a mitochondrial-derived peptide encoded by mitochondrial DNA
Despite aggressive marketing promoting these drugs as safe and effective, GLP-1 medications have been linked to severe health risks, including gastroparesisa condition where the stomach is paralyzed, leading to long-term gastrointestinal issues
Many patients notice their appetite suppression plateaus after 46 weeks at a given dose level
Even small increases in movement, like daily walks or interval training, can make a noticeable difference when combined with semaglutide
- [Stability of Peptide-Based Therapeutics: Storage Considerations]( *Journal of Pharmaceutical Sciences*, 2020